News & Updates
Filter by Specialty:
Add-on acalabrutinib prolongs PFS in older patients with untreated MCL
In older patients with untreated mantle cell lymphoma (MCL), the addition of the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to bendamustine and rituximab (ABR) conferred a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with a favourable trend for overall survival (OS), findings from the phase III ECHO trial have shown.
Add-on acalabrutinib prolongs PFS in older patients with untreated MCL
04 Sep 2024
STAMP inhibitor bests all TKIs in pivotal head-to-head CML study
In the phase III ASC4FIRST study, asciminib – the first BCR::ABL1 inhibitor to Specifically Target the ABL Myristoyl Pocket (STAMP) – trumped all investigator-selected tyrosine kinase inhibitors (IS-TKIs; imatinib, nilotinib, dasatinib, and bosutinib) for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP).
STAMP inhibitor bests all TKIs in pivotal head-to-head CML study
02 Sep 2024
Apremilast delivers favourable outcomes for patients with early oligoarticular PsA
In the treatment of patients with early oligoarticular psoriatic arthritis (PsA), the use of apremilast yields substantial improvements in both clinical and patient-reported outcomes, as shown in the results of the phase IV FOREMOST study.
Apremilast delivers favourable outcomes for patients with early oligoarticular PsA
01 Sep 2024
Tofacitinib safe, efficacious in ankylosing spondylitis regardless of baseline CRP
Tofacitinib demonstrates greater efficacy than placebo at week 12 in patients with ankylosing spondylitis (AS) regardless of their baseline C-reactive protein (CRP) levels, a study has shown.
